tradmap

KAPA Earnings Kairos Pharma, LTD.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$0 -$0 $0 2023 2024 2025
EPS
Net income (annual)
-$5M -$3M $0 2023 2024 2025
Net income
Return on equity (annual)
-86% 1% 87% 0% 2023 2024 2025
ROE

Quarterly results

Diluted EPS (quarterly)
-$0 -$0 $0 Q3 '23 Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26
EPS
Net income (quarterly)
-$2M $426000 $3M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income
Return on equity (quarterly)
-121% -52% 17% 0% Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
ROE

Reported EPS history

1–12 of 12
Q2 20262026-06-30-0.142026-08-1210-Q
Q1 20262026-03-31-0.082026-05-1310-Q
FY 20252025-12-31-0.302026-03-3110-K
Q3 20252025-09-30-0.232025-11-1410-Q
Q2 20262025-06-30-0.162026-08-1210-Q
Q1 20262025-03-31-0.082026-05-1310-Q
FY 20252024-12-31-0.232026-03-3110-K
Q3 20252024-09-30-0.152025-11-1410-Q
Q2 20252024-06-30-0.052025-08-1210-Q
Q1 20252024-03-31-0.032025-05-1410-Q
FY 20242023-12-31-0.172025-04-1510-K
Q3 20242023-09-30-0.072024-11-1410-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.